{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', '9.3', 'OTHER SECONDARY ENDPOINTS', '9.3.1 Systemic Drug Concentration, Anti-drug Antibodies, and IgG responses to', 'vaccination during drug treatment', 'Serum functional dupilumab concentrations', 'ADA', 'IgG responses to vaccination with any vaccination for tetanus, diphtheria, pertussis and/or', 'seasonal trivalent/quadrivalent influenza vaccine during dupilumab treatment (may be', 'analyzed as exploratory endpoint if insufficient power).', '9.3.1.1 Systemic Drug Concentration and Anti-drug Antibodies', '9.3.1.1.1.1 Sampling Time', 'Predose blood samples will be collected for determination of functional dupilumab concentration', 'in serum and anti-dupilumab antibodies (including neutralizing antibodies) on days designated in', 'the Study Flow Chart (see Section 1.2 as well as Section 10.3.4, as needed for Brazil). The date of', 'collection should be recorded in the patient e-CRF. The date and time also will be collected on the', 'central laboratory requisition form and entered into the database through data transfers from the', 'central laboratory.', 'If an SAE or AESI occurs in a patient, blood samples should be collected for determination of', 'functional dupilumab concentration, and anti-dupilumab antibody assessment at or near the onset', 'and completion of the occurrence of the event, if possible. The exact date and time of sample', 'collection must be recorded and entered into the database by the central laboratory. An', 'unscheduled systemic drug concentration page in the e-CRF must be completed as well.', 'Further follow-up of individual patients will be considered based on the overall assessment of', 'antibody titers and clinical presentation.', '9.3.1.1.2 Handling Procedures', 'Special procedures for collection, storage, and shipping of serum are described in separate', 'operational manuals. An overview of handling procedure for samples used in the determination of', 'systemic drug concentration and anti-drug antibodies is provided in Table 2.', 'Property of the Sanofi Group - strictly confidential', 'Page 69', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'Table 2 - Summary of handling procedures for dupilumab', 'Sample type', 'Functional dupilumab', 'Anti-dupilumab antibody', 'Matrix', 'Serum', 'Serum', 'Blood sample volume', '2 mL', '2 mL', 'Anticoagulant', 'None', 'None', 'Blood handling procedures', 'See Operational Manual', 'See Operational Manual', 'Serum aliquot split', 'Two aliquots', 'Two aliquots', 'Storage conditions', '<6 months: below -20\u00b0C', '<6 months: below -20\u00b0C', '<24 months: below -80\u00b0C (preferred)', '<24 months: below -80\u00b0C (preferred)', 'Serum shipment condition', 'In dry ice', 'In dry ice', '9.3.1.1.3.3.3.3 Bioanalytic Method', 'Serum samples will be assayed using validated methods as described in Table 3.', 'Table 3 - Summary of bioanalytical methods for dupilumab and anti-dupilumab antibody', 'Analyte', 'Functional dupilumab', 'Anti-dupilumab antibody', 'Matrix', 'Serum', 'Serum', 'ELISA', 'Electrochemiluminescence', 'Analytical technique', 'Site of bioanalysis', 'Regeneron', 'Regeneron', 'ELISA: enzyme-linked immunosorbent assay', '9.3.1.2 Humoral Immune Response to Vaccines', 'Humoral immune responses to standard vaccines (in this study: any vaccination for tetanus,', 'diphtheria, pertussis and/or seasonal trivalent/quadrivalent influenza vaccine) occurring during', 'dupilumab treatment will be evaluated for those patients eligible for these vaccinations.', 'At Screening, parent(s)/caregiver(s)/legal guardian(s) will be asked to provide information on', \"their child's vaccination record and schedule, and assess whether immunizing their children with\", 'any vaccination for tetanus, diphtheria, pertussis and/or seasonal trivalent/quadrivalent influenza', '(as per local medical practice) will result in vaccination during the study.', 'Any patient who will receive planned vaccination for tetanus, diphtheria, pertussis and/or seasonal', 'trivalent/quadrivalent influenza during the study, will be scheduled to receive the respective', 'vaccination(s) and to have blood samples for antibody titers drawn before and after the respective', 'vaccination(s), as detailed below, and as shown in the Study Flow Chart (Section 1.2).', 'Property of the Sanofi Group - strictly confidential', 'Page 70', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}